479 related articles for article (PubMed ID: 19483514)
1. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial.
Lucero MG; Nohynek H; Williams G; Tallo V; Simões EA; Lupisan S; Sanvictores D; Forsyth S; Puumalainen T; Ugpo J; Lechago M; de Campo M; Abucejo-Ladesma E; Sombrero L; Nissinen A; Soininen A; Ruutu P; Riley I; Mäkelä HP
Pediatr Infect Dis J; 2009 Jun; 28(6):455-62. PubMed ID: 19483514
[TBL] [Abstract][Full Text] [Related]
2. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.
Cutts FT; Zaman SM; Enwere G; Jaffar S; Levine OS; Okoko JB; Oluwalana C; Vaughan A; Obaro SK; Leach A; McAdam KP; Biney E; Saaka M; Onwuchekwa U; Yallop F; Pierce NF; Greenwood BM; Adegbola RA;
Lancet; 2005 Mar 26-Apr 1; 365(9465):1139-46. PubMed ID: 15794968
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity and tolerability of a non-adjuvanted 11-valent diphtheria-tetanus toxoid pneumococcal conjugate vaccine in Filipino children.
Ugpo J; Lucero M; Williams G; Lechago M; Nillos L; Tallo V; Nohynek H;
Vaccine; 2009 May; 27(20):2723-9. PubMed ID: 18977267
[TBL] [Abstract][Full Text] [Related]
5. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age.
Lucero MG; Dulalia VE; Parreno RN; Lim-Quianzon DM; Nohynek H; Makela H; Williams G
Cochrane Database Syst Rev; 2004 Oct; (4):CD004977. PubMed ID: 15495133
[TBL] [Abstract][Full Text] [Related]
8. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.
Lucero MG; Dulalia VE; Nillos LT; Williams G; Parreño RA; Nohynek H; Riley ID; Makela H
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004977. PubMed ID: 19821336
[TBL] [Abstract][Full Text] [Related]
9. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
Klugman KP; Madhi SA; Huebner RE; Kohberger R; Mbelle N; Pierce N;
N Engl J Med; 2003 Oct; 349(14):1341-8. PubMed ID: 14523142
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
[TBL] [Abstract][Full Text] [Related]
13. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugate vaccine--a health priority.
Zar HJ; Madhi SA
S Afr Med J; 2008 Jun; 98(6):463-7. PubMed ID: 18683380
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
Black SB; Shinefield HR; Ling S; Hansen J; Fireman B; Spring D; Noyes J; Lewis E; Ray P; Lee J; Hackell J
Pediatr Infect Dis J; 2002 Sep; 21(9):810-5. PubMed ID: 12352800
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
[TBL] [Abstract][Full Text] [Related]
18. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
Fitzwater SP; Chandran A; Santosham M; Johnson HL
Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
[TBL] [Abstract][Full Text] [Related]
19. Distance to health services modifies the effect of an 11-valent pneumococcal vaccine on pneumonia risk among children less than 2 years of age in Bohol, Philippines.
Root ED; Lucero M; Nohynek H; Stubbs R; Tallo V; Lupisan SP; Sanvictores DM; Nillos LT; Simões EA;
Int J Epidemiol; 2017 Apr; 46(2):706-716. PubMed ID: 27605588
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
